Technical Analysis for RVNC - Revance Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 22.47 0.49% 0.11
RVNC closed up 0.49 percent on Friday, January 17, 2020, on 87 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical RVNC trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
New 52 Week High Strength 0.49%
Upper Bollinger Band Walk Strength 0.49%
Wide Bands Range Expansion 0.49%
Above Upper BB Strength 0.49%
Overbought Stochastic Strength 0.49%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.
Biopharmaceutical Pain Drugs Migraine Plastic Surgery Toxins Botulinum Toxin Botulism Hyperhidrosis Neurotoxins Rhinitis

Is RVNC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.43
52 Week Low 10.0
Average Volume 724,205
200-Day Moving Average 13.76
50-Day Moving Average 17.01
20-Day Moving Average 17.87
10-Day Moving Average 19.55
Average True Range 0.96
ADX 33.92
+DI 45.10
-DI 7.83
Chandelier Exit (Long, 3 ATRs ) 20.54
Chandelier Exit (Short, 3 ATRs ) 18.26
Upper Bollinger Band 23.00
Lower Bollinger Band 12.73
Percent B (%b) 0.95
BandWidth 57.46
MACD Line 1.53
MACD Signal Line 0.83
MACD Histogram 0.6979
Fundamentals Value
Market Cap 692.51 Million
Num Shares 30.8 Million
EPS -3.44
Price-to-Earnings (P/E) Ratio -6.53
Price-to-Sales 2609.34
Price-to-Book 4.85
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.34
Resistance 3 (R3) 23.31 23.00 23.20
Resistance 2 (R2) 23.00 22.78 23.01 23.15
Resistance 1 (R1) 22.73 22.64 22.58 22.76 23.10
Pivot Point 22.42 22.42 22.34 22.43 22.42
Support 1 (S1) 22.15 22.20 22.00 22.18 21.84
Support 2 (S2) 21.84 22.06 21.85 21.79
Support 3 (S3) 21.57 21.84 21.75
Support 4 (S4) 21.60